- Trial phase
- Phase 3
- Time to market
- If Phase 3 trials succeed, a potential FDA filing would likely occur no earlier than 2028, given that the pivotal VESPER-6 monthly maintenance trial only opened enrollment in June 2026 and obesity trials typically run 12-18 months for primary completion.
- Why 4/10
- No hard dated catalyst (PDUFA or pivotal readout) is scheduled within the next ~12 months; the Phase 3 program (VESPER-4, -5, -6) is still enrolling patients. For a large, diversified pharma like Pfizer, berobenatide is one of many pipeline assets, so even a major readout would move the stock by a few percent, not a binary event.
The next catalysts are Phase 3 enrollment updates and any interim data from the VESPER-4, VESPER-5, or VESPER-6 trials, but no hard binary readout or PDUFA date is scheduled within the next 12 months. Positive Phase 3 data would validate the monthly-dosing thesis and could open a large market; negative data (efficacy miss or unexpected safety) would damage Pfizer's obesity strategy and the $10B Metsera acquisition thesis.
Price Chart
Executive Summary
Berobenatide is Pfizer's investigational ultra-long-acting GLP-1 receptor agonist for obesity and overweight, acquired through the ~$10 billion purchase of Metsera in November 2025. Phase 2b data presented at ADA June 2026 showed up to 12.3% placebo-adjusted weight loss with monthly maintenance dosing and a side-effect profile similar to Wegovy. Pfizer has launched an ambitious Phase 3 program with 10+ planned studies (VESPER-4, -5, -6, and comorbidity trials), but these trials are still enrolling with no near-term binary readout or PDUFA date. For a diversified giant like Pfizer, berobenatide is an important pipeline asset but not a stock-swinging catalyst in the next 12 months.
How It Works
Berobenatide is a GLP-1 receptor agonist, meaning it mimics a natural hormone that tells the brain you are full, slows stomach emptying, and helps control blood sugar. It is designed to be 'ultra-long-acting' by attaching tightly to a blood protein called albumin, which keeps it from breaking down quickly. This allows patients to inject it once a month instead of once a week like current GLP-1 drugs (Wegovy, Ozempic, Zepbound).
Trial Status
Berobenatide has completed Phase 2b (VESPER-1, -2, -3) with positive results presented at ADA June 2026. The Phase 3 program is underway: VESPER-4 (weekly, obesity without T2D) started late 2025/March 2026; VESPER-5 (weekly, obesity with T2D) is ongoing; VESPER-6 (monthly maintenance, pivotal) opened for enrollment in June 2026; VESPER-OSA 1 (sleep apnea) started September 2026. Pfizer plans 10+ Phase 3 studies total.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 enrollment completion updates for VESPER-4, VESPER-5, and VESPER-6 trials (ongoing, no specific dates announced); potential interim data from Phase 3 program (timing uncertain, likely 2027+); SOLIS-1 Phase 2b data for the amylin combination (PF'3945) with berobenatide.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report